Envoy Medical Says 10 Study Participants In First Stage Of Pivotal Clinical Trial For Fully Implanted Acclaim Cochlear Implant Completed One-Month Follow-Up Visits

Positive momentum from the trial's first stage encouraging Company to accelerate plans for expansion and commercialization

White Bear Lake, Minnesota--(Newsfile Corp. - June 10, 2025) - Envoy Medical®, Inc. (NASDAQ:COCH) ("Envoy Medical"), a revolutionary hearing health company focused on fully implanted hearing devices that leverage the ear's natural anatomy, today announced that all 10 of the study participants in the first stage of the Company's pivotal clinical trial for the fully implanted Acclaim® Cochlear Implant have successfully completed their one-month follow-up visits.

The investigational sites have reported that the visits are proceeding as expected. Due to the device's breakthrough design, participants are hearing without the need for externally worn devices and have the ability to hear 24 hours a day. No serious adverse events or unanticipated device events have been reported through the first month for all 10 participants.